EMEA-002578-PIP01-19-M01

First vaccine against epizootic haemorrhagic disease recommended for approval

Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 11-13 March 2025

Summary of opinion: Rheumocam, 13/03/2025 Positive

EMEA-002566-PIP01-19-M01

Frequently asked questions

EMEA-002559-PIP09-23

Frequently asked questions (FAQs): How to create, submit and withdraw a Clinical Trial Application - CTIS Training Programme - Module 10

Opinion/decision on a Paediatric investigation plan (PIP): Litfulo, Ritlecitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0026/2024

Opinion/decision on a Paediatric investigation plan (PIP): Sotyktu, Deucravacitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0008/2024